Evidence map›Paper›PMID 37257920›Full record

ArticleBMJ open gastroenterology2023

Dutch individuals' views of screening for oesophageal cancer: a focus group study.

Jasmijn Sijben, Yonne Peters, Sharell Bas, Peter Siersema, Linda Rainey, Mireille Broeders

Abstract read
In one paragraph

Article in BMJ open gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jasmijn SijbenDepartment of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Gelderland, The Netherlands jasmijn.sijben@radboudumc.nl.ORCID 0000-0003-0722-0586
Yonne PetersDepartment of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Sharell BasDepartment for Health Evidence, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Peter SiersemaDepartment of Gastroenterology and Hepatology, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Linda RaineyDepartment for Health Evidence, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Mireille BroedersDepartment for Health Evidence, Radboudumc, Nijmegen, Gelderland, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveScreening for early oesophageal adenocarcinoma (OAC), including its precursor Barrett's oesophagus (BO), can potentially reduce OAC-related morbidity and mortality. This study explores Dutch at-risk individuals' views of screening an at-risk population for BO/OAC.

designWe invited 372 individuals with risk factors for OAC from primary care practices, 73 individuals with surveillance experience, and 221 participants of previous studies (BO/OAC screening trial or survey) to participate in focus groups. Transcripts were inductively and thematically analysed by two independent researchers.

resultsA total of 50 individuals (42% with gastro-oesophageal reflux symptoms) of 50-75 years participated. Themes that were raised included: theme 1 'screening intentions' describing participants' motivation to be screened (eg, early diagnosis, potential reassurance, physician recommendation, and knowing someone with cancer) or decline screening (eg, anticipated discomfort or suboptimal accuracy of the test); theme 2 'risk-based eligibility' describing the tension between effectiveness (eg, targeting high-risk individuals) and inclusivity (eg, making screening available for everyone); theme 3 'distributive justice', in which the pressure of a potential new screening programme on healthcare resources was discussed; and theme 4 'information needs' describing the perceived lack of information access and individuals' preference to discuss screening with their general practitioner.

conclusionIndividuals not only expressed high willingness to be screened but also voiced the concern that a new screening programme may pressure limited healthcare resources. If implemented, it is crucial to develop educational materials that meet the public's information needs and explain the test procedures and eligibility criteria while avoiding stigmatising language.

Indexed as

Barrett EsophagusEsophageal NeoplasmsAdenocarcinomaEarly Detection of CancerFocus GroupsHumansBarrett's metaplasiaBarrett's oesophaguscancer preventiongastroesophageal reflux diseaseoesophageal cancer

Identifiers

PMID37257920
PMCPMC10254588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.